Biotech company CSL Limited will supply the Australian Government with 51 million doses of The University of Queensland’s COVID-19 vaccine candidate if it proves successful, under a heads of agreement announced today. CSL expects the first tranche of doses to be available by mid-2021, with additional doses following in late 2021 and early 2022, if … Continue reading CSL signs agreement with Australian Government for UQ vaccine supply
Pre-clinical testing of The University of Queensland’s COVID-19 vaccine has produced positive indications about its potential effectiveness and ability to be manufactured. Project co-leader associate professor Keith Chappell has reported to the International Society for Vaccines on data from animal trials conducted by Viroclinics-DDL in the Netherlands. “The neutralising immune response created by our molecular … Continue reading UQ vaccine scientists report positive results from pre-clinical testing
Australian biotech giant CSL has formed a consortium with Takeda Pharmaceutical Company to develop a potential plasma therapy to fight coronavirus. The alliance, which also brings together leading biomedical manufacturers Biotest, BPL Medical Technologies, LFB and Octapharma, will leverage expertise within each company to develop trials. CSL Behring’s executive vice president and head of research … Continue reading CSL consortium to make plasma against coronavirus
A new strategic partnership between Siemens and Cuthbert Stewart Limited (CSL) will see more manufacturing products sold in New Zealand through the APS master distributor. Siemens’ factory automation, related communications, drives and process instrumentation equipment will be available under as part of an existing and continuing partnership with J.A Russell for low voltage products. Siemens … Continue reading Siemens expands APS Industrial distribution partnership into New Zealand
Caltex Australia has topped the list of Australia’s leading manufacturers for 2020 for the second consecutive year, with this year’s ‘Top 100’ reflective of Australia’s investments in advanced manufacturing, reputation for high-quality production and the depreciation of the dollar. The list consists of 29 ASX-listed companies and 37 locally owned companies, according to the Advanced … Continue reading Australia’s top 100 manufacturers for 2020 revealed
CSL has announced that it has agreed to acquire 80 per cent equity of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products (“Ruide”) from Humanwell Healthcare Group (“Humanwell”) for US$352 million. The transaction will provide CSL with a strategic presence in the Chinese domestic plasma fractionation market, and complements the leadership position that … Continue reading CSL to acquire majority stake in Chinese manufacturer Ruide
Melbourne-based biotech manufacturer CSL says the slowing of China’s economy will not affect its Asian expansion plans.
Pharmaceutical giant CSL will farewell its CEO Brian McNamee who has been one of Australia’s longest-serving chief executives.
A combination of ongoing industrial relations issues and a strong Aussie dollar have prompted healthcare manufacturer CSL to consider moving manufacturing operations offshore.
Pharmaceutical manufacturer CSL today revised their US Dollar profit outlook for 2013 up.
The first of CSL’s new buildings from a $250 million investment at its Broadmeadows site will start producing biopharmaceuticals for clinical trials early next year.
CSL Biotherapies, a subsidiary of CSL Limited Australia and one of the world’s leading manufacturers of influenza vaccine, has announced it has been awarded a contract by the United States Department of Health Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.
Australian Pharmaceutical manufacturing looks set for substantial growth to meet the increasing demand of Asian health-care products.